WHAT’S OUR STORY?

We are on a mission to impact patients’ lives.

We have potentially groundbreaking clinical-stage therapies in development that, if approved, offer an innovative approach to essential areas of dermatology.

OUR STORY STARTS HERE

We are proud to announce the FDA approval of our first treatment
WINLEVI® (clascoterone) cream 1%

Read more

LATEST NEWS

December 23, 2020
chevron right icon

Cassiopea Announces Management Change

October 8, 2020
chevron right icon

Cassiopea Announces Completion of Enrollment in a Phase II Trial of Clascoterone Solution for the Treatment of Androgenetic Alopecia in Females

August 27, 2020
chevron right icon

Cassiopea Receives FDA Approval for Winlevi® (clascoterone cream 1%), First-in-Class Topical Acne Treatment Targeting the Androgen Receptor

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved.